ArticleLeukemia2020
Risk of HBV reactivation post CD19-CAR-T cell therapy in DLBCL patients with concomitant chronic HBV infection.
Abstract readLetter
In one paragraph
Article in Leukemia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Risk of HBV Reactivation in Patients With Resolved HBV Infection Receiving Anti-CD19 Chimeric Antigen Receptor T Cell Therapy Without Antiviral Prophylaxis.Frontiers in immunology · 2021Trial
- Review
- Immune escape mechanisms and therapeutic advances in virus-associated hematological malignancies.Blood cancer journal · 2026Review
- Chimeric antigen receptor T‑cell therapy in chronic viral infections: a review.Journal of translational medicine · 2026Review
- Antineoplastic agents-associated hepatitis B virus reactivation: Research progress and molecular mechanisms.Virus research · 2025Review
- The interplay between hepatitis B virus and antitumor drugs in the treatment of hepatocellular carcinoma.Clinical and experimental medicine · 2025Review
- Drug-Induced Liver Injury Associated With Emerging Cancer Therapies.Liver international : official journal of the International Association for the Study of the Liver · 2025Review
- Post-Chimeric Antigen Receptor T-Cell Therapy Hepatitis B Virus Reactivation After 23 Months of Entecavir Prophylaxis.ACG case reports journal · 2024Article
- Case report: CAR-T therapy demonstrated safety and efficacy in relapsed/refractory diffuse large B-cell lymphoma patients complicated with hepatitis B-related cirrhosis.Frontiers in oncology · 2024Article
- Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies in the targeted therapy era.World journal of gastroenterology · 2023Review
- Strategies to optimize chimeric antigen receptor T-cell therapy in hematologic malignancies: Chinese experience.Haematologica · 2023Review
- HBV-associated DLBCL of poor prognosis: advance in pathogenesis, immunity and therapy.Frontiers in immunology · 2023Review
- Efficacy and safety of chimeric antigen receptor T cell therapy in relapsed/refractory diffuse large B-cell lymphoma with different HBV status: a retrospective study from a single center.Frontiers in immunology · 2023Article
- Antiviral therapy use and related outcomes in patients with cancer and viral infections: results from SWOG S1204.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Article
- Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy.Bone marrow transplantation · 2022Review
- [Drugs and hepatitis B virus reactivation].Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi · 2022Article
- [The Chinese consensus for the CAR-T cell therapy in multiple myeloma (2022 version)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2022Article
- [How I manage B cell lymphoma patients treated with CD19 specific CAR-T cell throughout whole-process management].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2022Article
- Protective Role of Rheumatic Diseases Against Hepatitis B Virus Infection and Human Leukocyte Antigen B27 Highlighted.Frontiers in medicine · 2022Article
- Risk of HBV reactivation in relapsed or refractory diffuse large B-cell lymphoma patients receiving Bruton tyrosine kinase inhibitors therapy.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Chunmei Yang *Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, Zhejiang, China.
Mixue Xie *Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, Zhejiang, China.
Kaifeng ZhangInstitute of Hematology, Zhejiang University, Hangzhou, 310003, Zhejiang, China.
Hui LiuDepartment of Hematology, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310009, Zhejiang, China.
Aibin LiangDepartment of Hematology, Tongji Hospital of Tongji University, Shanghai, 200065, China. lab7182@tongji.edu.cn.ORCID http://orcid.org/0000-0002-8978-1987
Ken H YoungHematopathology Division and Department of Pathology, Duke University School of Medicine, Duke University Medical Center and Cancer Institute, Durham, NC, 27710, USA. ken.young@duke.edu.ORCID http://orcid.org/0000-0002-5755-8932
Wenbin QianInstitute of Hematology, Zhejiang University, Hangzhou, 310003, Zhejiang, China. qianwb@zju.edu.cn.ORCID http://orcid.org/0000-0002-9817-6674
Funding
National Natural Science Foundation of China (National Science Foundation of China) 81830006, 81830004, 81670178Natural Science Foundation of Zhejiang Province (Zhejiang Provincial Natural Science Foundation) LY18H16008Natural Science Foundation of Zhejiang Province (Zhejiang Provincial Natural Science Foundation) LY20H080006Science and Technology Department of Zhejiang Province 2018C03016-1
Abstract
PubMed holds no abstract for this paper.
Indexed as
Hepatitis B virusVirus ActivationAntigens, CD19Hepatitis B, ChronicHumansImmunosuppressive AgentsImmunotherapy, AdoptiveLymphoma, Large B-Cell, DiffuseViral LoadAntigens, CD19Immunosuppressive Agents
Identifiers
PMID
32533094What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.